The Association for the Cannabinoid Industry (ACI) is a membership organisation for businesses committed to nurturing a safe, legal and flourishing commercial cannabis extract market in the UK and Europe.
Our vision is to create an innovative and ethical sector with the highest standards of product quality, consumer satisfaction and regulatory compliance. All our members sign up to our quality charter.
We deliver vital stewardship for this emerging sector through constructive engagement with key stakeholders and thought leaders. To find out what we’ve achieved see our list of milestones.
Our team of scientific, regulatory and industry leaders provide expert support and guidance to our members.
ACI in the Media
CBD brands have had more than a year to sort out their novel food applications, but only three have made the grade so far. The Grocer investigates what’s going on?
As Novel Food regulations for CBD products come into effect, Jersey Hemp speaks to ACI’s External Affairs director Shomi Malik about the importance of robust, relevant scientific data in moving the industry into the mainstream.
The Association for the Cannabinoid Industry (ACI) has publicly refuted the content and claims made in a letter published and shared widely on social media on Friday 26 March 2021.
Results from a major US trial over 800 people over the past seven months found CBD use has zero impact on the liver. ACI member, Columbia Care, Charlotte’s Web and 10 other US companies provided around $1m for a trial which started last summer – and now appears to have answered the CBD safety question.
CBD industry experts have put together a detailed safety review of THC recommending clear policy recommendations to cut market confusion reports NutraIngredients
Canex cover news of the release of our detailed safety review report on THC.
As outlined in ACI’s report “Health Guidance Levels for THC in CBD products,” the industry group recommend that the UK Home Office enacts a cap of 0.021 mg/kg of THC (and other cannabinol derivatives) per day. This limit would be equivalent to permitting 0.03 percent THC per the recommended 70 mg daily intake of CBD.
ACI member Treehouse Biotech has submitted a Novel Foods application to UK authorities for its Cannabidiol (CBD)-based ingredients in a move that signals the US firm’s intent to capture a slice of the UK’s burgeoning CBD market.
Pharmacy Business Magazine reports that the FSA updated the criteria for CBD products which can remain on sale from 1 April 2021. Previously, only products which were on sale at the time of the FSA’s announcement (13 February 2020) and were linked to an application which had been validated by 31 March 2021 were to be included.